The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. METHODS: Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. RESULTS: One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2:1 (extract N = 102; placebo N = 64; juice N = 17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P o 0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004). However, none of these changes were statistically significant between the three groups (P40.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P = 0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P = 0.03). CONCLUSIONS: Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.
INTRODUCTION
There is widespread interest in dietary approaches for prostate cancer prevention and treatment. It has been estimated that 30% of prostate cancer patients are using complementary alternative medicine in addition to standard treatments. 1 One such approach has included the consumption of pomegranate juice. Pomegranate phytochemicals have been shown to be effective in reducing oxidative stress and to modulate inflammatory pathways. 2, 3 Moreover, pomegranate juice and its antioxidant metabolites have been extensively studied preclinically for their in vivo and in vitro effects on prostate cancer cells, [4] [5] [6] [7] [8] [9] and clinically for their impact on serum PSA kinetics. Two single-arm, uncontrolled phase II clinical studies have supported the biological activity of pomegranate extracts in biochemically recurrent human prostate cancer 10, 11 as demonstrated by statistically significant prolongations in PSA doubling times (PSADT) relative to prestudy PSADT (that is, a more slowly rising PSA). However, the lack of placebo control in both of these single-arm studies, combined with the fact that a prior placebo-controlled trial found that a majority of men assigned to placebo on a similarly designed study also had a longer on-study PSADT than prestudy, 12 makes interpretation of these data challenging. As such, the primary objective of this multicenter, double-blind study (NCT00336934) was to compare the effects of the daily consumption of pomegranate liquid extract on end-of-treatment PSADT in a placebo-controlled manner. Moreover, the study attempted to prospectively investigate a gene-nutrient interaction involving the manganese superoxide dismutase (MnSOD) gene, antioxidant status, and prostate cancer. At the time of study design in 2005, Li et al. 13 reported data that suggested that men with the MnSOD AA genotype represent a genetic subgroup that were most susceptible to low antioxidant status and would theoretically benefit the greatest from antioxidant supplementation. Therefore samples for MnSOD genotyping were collected from subjects at baseline to determine, in an exploratory manner, the interaction between AA genotype and PSADT.
MATERIALS AND METHODS

Study design
This clinical trial was a double-blind, multicenter, parallel-group study to evaluate the effects of pomegranate liquid extract or placebo treatment on serum PSA kinetics. Patients received 8 oz of pomegranate liquid extract (equivalent to 1.6 mmol of total polyphenols per day) or matching liquid placebo daily until PSA progression criteria were met. Subjects on concomitant prostate cancer treatments including androgen-regulating agents capable of impacting PSA levels (for example, 5-alpha reductase inhibitors, androgen receptor inhibitors and so on) were excluded from participation. Originally designed as a 300 subjects three-arm study of placebo, pomegranate extract and standard pomegranate juice with 1:1:1 randomization between the three arms, the study was converted in April 2007 (1 year after study initiation) to a 180 subjects two-arm study with 2:1 randomization (extract:placebo) because of slow accrual. Treatment effect size and study power were unchanged by the change in number of study arms. The clinical trial was approved by the appropriate institutional review boards, registered with clinicaltrials.gov (NCT00336934), and overseen by an independent Data Safety and Management Board.
The primary objective was to compare the effects of pomegranate liquid extract versus placebo on serum PSADT. Additional objectives included assessment of the tolerability and toxicity of the pomegranate treatment, and to determine the impact of MnSOD AA genotype on treatment effect. All patients were required to have a documented rising serum PSA following treatment with three rising serum PSA time points over a minimum of 6 months above the minimum nadir achieved. Patients returned for clinical and laboratory evaluation every 13 weeks.
Study test product
Pomegranate extract (juice, extract and placebo provided by the study sponsor, Pom Wonderful, Los Angeles, CA, USA) is a commercially available pomegranate (Punica granatum L., Wonderful variety) fruit polyphenol extract developed for use as a nutritional supplement. Product specifications have been established, and the extract has been well characterized and contains the same compounds found in pomegranate juice, differing only in having lower anthocyanidins and significantly higher proportional content of pomegranate polyphenols, primarily punicalagin and isomers.
Sample size determination
An evaluable sample of 90 subjects in the active group and 50 subjects in the placebo group was estimated to provide 90% power (α = 0.05, two-tailed) to detect a difference in mean PSADT between placebo and active treatment groups of 19.5 months following 12 months of treatment. To account for lack of compliance and subject attrition, 180 subjects were randomized in a ratio of 2:1, with 120 subjects in the active group and 60 subjects in the placebo group. Assumptions were based on the prior University of California-Los Angeles (UCLA) phase 2 study. 10 Although the phase 2 study published a mean PSADT delta of 39 months following 3 years of treatment with pomegranate juice compared with baseline, data from the phase 2 study was used to estimate a PSADT effect size for a planned 12 months of treatment.
Study end points and analyses
The primary efficacy outcome was PSA doubling time assessed from baseline to end-of-treatment. PSA doubling time was compared using a random slope linear regression model of log PSA on time elapsed of the form: ln PSA ð Þ¼a i þ b i time þ error in each treatment group:
In this mixed random effects model, each patient has his own slope (b i ) in units of log PSA change per unit time and his own intercept (a i ) in log PSA units. The estimated doubling time for the ith patient is ln(2)/b i . If (log) PSA decreases (negative b i ), the 'negative' doubling time is a halving time. The time to disease progression was defined as the first time from start of treatment where there is a 100% increase in PSA compared with baseline pretreatment levels with a minimum increase of 1.0 ng ml − 1 , or the first post-treatment time any documented of metastatic or recurrent disease occurs. Progression (progression of disease) incidence was estimated using the Kaplan-Meier method, and the curves and corresponding event rates were compared between groups using the log rank test.
MnSOD genotyping
MnSOD genotyping was performed by the UCLA Genotyping and Sequencing Core of the Jonsson Comprehensive Cancer Center. Somatic DNA was obtained from blood-derived buffy coat samples taken at baseline before treatment initiation. An amount of 10ng μl of extracted DNA per study subject were used for a PCR-based allelic discrimination single-nucleotide polymorphism sequencing assay from Applied Biosystems (Waltham, MA, USA). PCR products are resolved using the ABI-3730 data collection software and sized by application of the Genemapper software package from Applied Biosystems. Two positive control samples of CEPH 1347-2 per 96-well plate are used to validate the accuracy of genotype calls for each marker. The computer-generated genotypes are checked by technicians blind to disease diagnosis and family structure. The called genotypes are imported to a relational database for error checking.
RESULTS
Patients
A total of 215 subjects were screened to obtain 183 eligible subjects from 18 study centers who were randomly assigned to the active and placebo groups with a ratio of 2:1 (extract N = 102; placebo N = 64; juice N = 17) ( Figure 1 ). Dates of enrollment of subjects spanned April 2006 to May 2009. The majority of subjects were Caucasian, underwent prior surgery or radiation therapy as primary treatment, and were initially staged as T2c or less. Mean subject age, original prostate cancer treatment modality, tumor stage, Gleason grade and PSA at time of study entry were similar across treatment groups. Demographic characteristics between the treatment groups were not significantly different and are presented in Table 1 . Mean baseline PSA was 1.23 ng ml − 1 in the placebo group and 1.25 ng ml − 1 in the Extract (P = 0.94). Of the 183 subjects (two main arms) who were randomized and enrolled into the main study, 128 completed the planned 12 months of treatment. The most common cause (41%) for early termination of study treatment was due to meeting criteria for disease progression. Rates of treatment completion and early study termination were similar across treatment arms. Reasons for early termination of treatment were not significantly different and are presented in Table 2 .
Safety and tolerability
The majority of adverse events (AEs) were of moderate or mild grade, and the overwhelming majority of AEs were judged as unrelated (87%) or unlikely related (9%) to study product in all groups. The overall rate of AEs in the placebo group was similar to the overall rate of AEs in the extract group. Only 3 out of 284 AEs were judged definitely related to study product, all three occurring in the Extract arm, and included gastrointestinal events such as nausea, constipation and decreased appetite. Possible additional AEs related to treatment included teeth discoloration and abdominal bloating. Severe or life threatening AEs including death were rare in all groups (n = 11 total), and none of the severe/ life threatening AEs were judged to be related to study product.
Efficacy
The primary outcome measure was the change in PSADT from baseline to end-of-treatment. The median doubling time increased 4.5 months from 11.1 months at baseline to 15.6 months in the placebo group (P o0.001, 95% confidence bounds 14.8-27.9 months) compared to a 1.6 month increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13, 95% confidence bounds 11.2-22.8 months) and a 7.6 month increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004, 95% confidence bounds 8.5-29.5 months). However, none of mean rate changes (post-minus predifferences) are statistically significant between the three groups using the P o 0.05 criterion. For placebo versus extract, the P-value for change in median PSADT was 0.14.
An additional analysis was performed in patients who received a minimum of 12 months of blinded treatment to determine whether length of treatment had any additional impact on PSADT. Median PSADT increased 3.5 months in Placebo patients from 12.2 at baseline to 15.7 months (Po 0.0001), 18 months from 16.1 at baseline to 34.1 months in juice patients (P = 0.05) and 5.6 months from 13.9 at baseline to 19.5 months in Extract patients (P = 0.0003).
Analysis of time to disease progression demonstrated no statistical differences between the placebo and extract groups. In the placebo group, 19 patients progressed after 1100.7 personmonths of follow-up, for an overall progression rate of 1.73 events per 100 person-months of follow-up. In the extract group, the progression rate was 1.97 events per 100 person-months (P = 0.51 compared with placebo). Cumulative incidence of disease progression by treatment is shown in Figure 2 .
MnSOD single-nucleotide polymorphism genotyping was performed in 159 available samples from the 183 subjects. Of these, AA genotype was observed in 34 (22%) of subjects. A protocol prespecified analysis of MnSOD AA subjects according to genotype and treatment arm showed that placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months, whereas extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months, and Juice patients experienced a 11.3 month change in median PSADT from 13.0 at baseline to 24.3 months. The P-value for PSADT change was significant (P = 0.03) in the AA extract patients, and did not reach significance in the AA Placebo patients (P = 0.22).
Compliance
As a measure of treatment compliance, urine samples obtained at study week 26 were analyzed by liquid chromatography-mass spectrometric high-performance liquid chromatography for levels of urolithin A glucuronide and dimethyl ellagic acid glucuronide using assays calibrated to references previously developed and characterized at the UCLA Center for Human Nutrition. Mean urolithin A glucuronide in ng ml − 1 was 732 in the extract group 
DISCUSSION
The main findings of this clinical trial are fourfold. First, the primary end point for the study was negative; the study was not able to demonstrate an overall PSADT change in the treatment arm that was statistically different from that seen in the placebo arm. Second, a significant prolongation in PSADT from baseline to post-treatment assessment was observed in both the treatment and placebo arms. Third, a preplanned subset analysis of the study cohort suggests that men with the MnSOD AA genotype may represent a group that is more sensitive to the effects of antioxidants. Finally, urinary measurements of pomegranate metabolites can serve as an indicator of pomegranate exposure and treatment compliance.
Adenocarcinoma of the prostate is currently the most common solid malignancy in men in the United States, comprising nearly a third of all cancers, and the second most common cause of cancer death. 14 Although radical surgery or radiation therapy is adequate for permanent disease control in many patients, biochemical PSA failure is commonly seen. 15, 16 There are currently no curative or nontoxic treatment options for patients who have biochemical recurrence following primary therapy.
Oxidative stress represents an imbalance in the intracellular production and clearance of reactive oxygen species, with the accumulation of intracellular free radicals that can damage all components of the cell, including damage to DNA. 17 There is substantial evidence that supports an important link between inflammation, reactive oxygen species and prostate carcinogenesis. 18, 19 Inflammation in the prostate microenvironment is thought to stimulate the process of carcinogenesis through a variety of cellular and molecular mechanisms, and there is evidence to support that proliferative inflammatory atrophy in benign prostate epithelium may be a precursor to both prostatic intraepithelial neoplasia and prostate cancer. 20 Not a phenomenon unique to just prostate cancer, oxidative stress, low levels of protective antioxidative enzymes and defective DNA repair of oxidative DNA damage, have all been implicated as having roles in carcinogenesis. 20, 21 A combination of epidemiologic and basic science evidence strongly suggests that diets rich in plant-derived phytochemicals may have cancer preventive benefits. Numerous phytochemicals have been proposed as potential chemoprevention agents based on animal and laboratory evidence of antitumor effects. Many of these agents function as potent antioxidants. However, evidence is accumulating for other mechanisms as well, including the inhibition of growth factor receptor signaling, promotion of cellular differentiation, the induction of hepatic xenobiotic enzyme activities which may provide additional defense mechanisms against oxidant stress and carcinogens, modulation of phosphodiesterase and cyclooxygenase pathways and through inhibition of protein kinases involved in cell signaling.
The pomegranate (P. granatum L.) fruit has been used for centuries in ancient cultures for its medicinal purposes, 22 and pomegranate juice has been shown to be a rich source of polyphenolic flavonoids which are compounds found in plants that are potent antioxidants. A significant body of literature provides evidence for the biological activity of pomegranate extracts in prostate cancer cells. In vivo and in vitro studies have shown that pomegranate extracts are capable of inhibiting tumor cell proliferation, migration, invasion, while also inducing apoptosis. [23] [24] [25] [26] For example, our institution has demonstrated the inhibitory effects of pomegranate extracts on the nuclear factor-kappaB inflammatory pathway. 3 Nuclear factor-kappaB is an important predictor of prostate cancer biochemical recurrence 27, 28 and is activated in castration-resistant prostate cancer. 29 Our investigations have demonstrated that inhibition of nuclear factor-kappaB is necessary for the maximal pro-apoptotic effect of pomegranate extracts.
Two small, nonplacebo controlled studies have provided clinical evidence for the biological activity of pomegranate extracts in human prostate cancer, determined primarily through impact on PSADT. In a single center phase II study, the effects of daily consumption of 8 oz. of pomegranate juice on PSA progression in 46 men with a biochemical recurrence after surgery or radiation were assessed. 10 There was a statistically significant prolongation of the PSADT from a mean of 15 months at baseline to 54 months after treatment (P o0.001). More recently, Paller et al. 11 published a multicenter phase II clinical trial of men with localized prostate cancer who received either 1 or 3 g of POMx, a standardized pomegranate polyphenol extract, daily. In this study, PSADT lengthened from 11.9 months at baseline to 18.8 months after treatment in the intention to treat group (P o 0.001), however there was no evidence of dose-response impact on PSADT between the two dosage groups (P = 0.554). Major criticisms of these two phase II studies have been the lack of placebo control and the lack of a dose-response effect observed. Moreover, the fact that a prior placebo-controlled trial found 73% of men on placebo on a similarly designed study had longer on-study PSADT than prestudy 12 makes interpreting these data challenging.
The current multicenter, randomized, double-blind, placebocontrolled clinical trial was designed to overcome these shortcomings and to validate their preliminary findings. Though the study failed to demonstrate an overall PSADT treatment effect statistically different from that seen in the placebo arm, data from a preplanned analysis of the current study showing statistically significant prolongation of PSADT in MnSOD AA patients treated with pomegranate compared with controls suggest that patients with the AA genotype of the MnSOD gene may represent a subpopulation of patients that is particularly susceptible to the effects of antioxidants. MnSOD is the primary antioxidant in the mitochondria, and its primary function is to convert reactive oxygen species to oxygen and hydrogen peroxide, 13 but it has also been reported to have additional tumor suppressor functions. 30 A polymorphism of MnSOD leading to either valine (V) or alanine (A) at codon 16 in its mitochondrial targeting sequence has been previously reported, and it has been further suggested that AA homozygous individuals have greater MnSOD enzyme activity that either VV homozygous of AV heterozygous individuals, 31 leading to increased oxidative cellular toxicity due to increased DNA damage from increased formation of 8-hydroxy-2′deoxyguanosine (8-OHdG), 32 or due to unquenched hydrogen peroxide in subjects with either high oxidative stress or low dietary antioxidant levels. 13 Several studies 13, 33 have previously demonstrated that there is a significant interaction between MnSOD polymorphism genotype, plasma antioxidant levels, and risk of prostate cancer with men with the AA, but not VA or VA, genotype having a fivefold gradient in risk for aggressive prostate cancer when analyzed by antioxidant level quartiles, showing men with MnSOD AA genotype at greatest risk when antioxidant status is low, presumably making this subgroup the most susceptible to the effects of dietary antioxidant supplementation.
PSADT, though widely recognized as an important prognostic and surrogate biomarker for prostate cancer mortality in men with rising PSA after primary treatment failure, 34, 35 is controversial when used as an end point in clinical trials. It is intuitive that, since men with a greater PSADT experience a longer survival than those with a shorter PSADT, that implementation of strategies to prolong PSADT would be indicative of effective therapy; however, there remains significant debate and controversy regarding the actual predictive value of changes in PSADT, and others have argued for the use of other end points such as progression-free survival in phase II studies. 36 In a small randomized study of the peroxisome proliferator-activated receptor γ-inhibitor rosiglitazone in men with prostate carcinoma and a rising serum PSA level, 38% of men in the placebo arm experienced a favorable outcome, defined as a post-treatment PSADT 4150% of the baseline PSADT. 12 Recently, is has been suggested that PSADT changes of this magnitude can be explained by natural variation in PSADT in patients with biochemically recurrent prostate cancer. 37 Paller et al. 37 have recently shown in a retrospective study that PSA variability in such men can lead to a natural lengthening of PSADT over time, and they suggest that increase in PSADT of 6 months or less, even when statistically significant, are unlikely to be clinically meaningful in the absence of a placebo control and their use to be interpreted with caution in uncontrolled single-arm studies. Recently, Antonarakis et al. 38 preformed a hypothesis-generating retrospective analysis of 4 phase II trials that suggests that within- Placebo controlled study of pomegranate in recurrent prostate cancer subject changes in PSADT and PSA slope after initiation of experimental therapy may correlate with metastasis-free survival in men with biochemically recurrent prostate cancer, though their findings require prospective validation. Never the less we show that testing the hypothesis that utilizing dietary manipulation with candidate compounds in the setting of select prostate cancer patients with rising PSA post local therapy is safe and feasible. Further, the findings with respect to MnSOD genotype and prolongation of PSADT with pomegranate dietary supplementation are provocative and deserve further exploration.
CONCLUSIONS
The study was not able to demonstrate an overall PSADT treatment effect in the treatment arms that was statistically different from that seen in the placebo arm. A preplanned subset analysis of the study cohort suggests that men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate and other antioxidants on PSADT; however, this finding requires prospective hypothesis testing and validation. Urinary measurements of pomegranate metabolites can serve as an indicator of pomegranate exposure and treatment compliance.
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